DBP and fibrosarcoma: Mice bearing the fibrosarcoma and receiving Dbp shRNA-engineered T cells showed less effective at eliminating tumor than normal Th9 cell-injected mice (Fig. 6d) and larger tumor size and increased weight (Fig. 6e) than did mice that received control shRNA-treated T cells, whereas mice that received E2f8 shRNA-engineered T cells showed significantly slower tumor growth (Fig. 6d) and reduced weight (Fig. 6e) than did mice that received control shRNA-treated T cells.